Related Experiment Videos
ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins
1Department of Medicine, University of Washington, Seattle 98195, USA. joram@u.washington.edu
Insights
The ATP binding cassette transporter ABCA1 facilitates cholesterol removal from cells, crucial for generating HDL and preventing atherosclerosis. Mutations in ABCA1 lead to Tangier disease, highlighting its role in lipid metabolism and cardiovascular health.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Science
Background:
- Apolipoproteins are key in cellular lipid transport.
- The ATP binding cassette transporter ABCA1 (formerly ABC1) controls an active pathway for removing cellular cholesterol and phospholipids.
- Mutations in ABCA1 result in Tangier disease, characterized by low HDL, rapid apolipoprotein A-I turnover, and sterol accumulation in macrophages.
Purpose of the Study:
- To elucidate the role of the ABCA1 pathway in apolipoprotein lipidation and HDL biogenesis.
- To understand the implications of ABCA1 mutations in Tangier disease and atherosclerosis.
- To highlight the ABCA1 pathway as a therapeutic target for cholesterol mobilization and atherosclerosis prevention.
Main Methods:
- Investigated the mechanism of cellular cholesterol and phospholipid removal.
- Studied the function of ABCA1 in apolipoprotein A-I lipidation.
- Analyzed the consequences of ABCA1 mutations in a clinical context (Tangier disease).
Main Results:
- The ABCA1 pathway is essential for the lipidation of apolipoprotein A-I.
- This lipidation process is required for the generation of High-Density Lipoprotein (HDL) particles.
- Deficiency in ABCA1 function leads to sterol accumulation in tissue macrophages and is linked to atherosclerosis.
Conclusions:
- The ABCA1 pathway is critical for maintaining cellular lipid homeostasis.
- Effective lipidation of apolipoprotein A-I via ABCA1 is necessary for HDL production and cholesterol efflux from macrophages.
- Targeting the ABCA1 pathway offers a potential therapeutic strategy for managing hyperlipidemia and reducing atherosclerosis risk.
Abstract:
Lipid-poor apolipoproteins remove cellular cholesterol and phospholipids by an active transport pathway controlled by an ATP binding cassette transporter called ABCA1 (formerly ABC1). Mutations in ABCA1 cause Tangier disease, a severe HDL deficiency syndrome characterized by a rapid turnover of plasma apolipoprotein A-I, accumulation of sterol in tissue macrophages, and prevalent atherosclerosis. This implies that lipidation of apolipoprotein A-I by the ABCA1 pathway is required for generating HDL particles and clearing sterol from macrophages. Thus, the ABCA1 pathway has become an important therapeutic target for mobilizing excess cholesterol from tissue macrophages and protecting against atherosclerosis.